Categories
Home
Irinotecan hydrochloride trihydrate 40mg/2ml
NAME OF THE MEDICINE
Irinotecan Onkovis
Irinotecan hydrochloride trihydrate 20 mg/ml, concentrate for solution for infusion
COMPOSITION
1ml Irinotecan onkovis contains 20mg/ ml concentrate for solution for infusion of irinotecan hydro- chloride, trihydrate (equivalent to 17.33 mg/ ml Irinotecan)
INDICATIONS
Irinotecan onkovis is indicated for the treatment of patients with advanced colorectal cancer:
- In combination with 5- fluororacil and folinic acid in patients without prior chemotherapy for advanced disease
- As a single agent in patients who have failed an established 5- fluorouracil containing treat- ment regimen.
Irinotecan onkovis in combination with cetuximab is indicated for the treatment of patients with EGFR (epidermal growth factor receptor )-expressing colorectal cancer in cases where Irinotecan containing cytotoxic therapy failed
Irinotecan oncovis in combination with 5-fluorouracil, folnic acid and bevacizumab is indicated for first line treatment of patients with metastatic carcinoma of the colon of rectum.
PRESENTATION
1 vial containing 2 ml solution
Multiple pack with 5 or 10 packs of 1 vial of 2 ml solution each.
MANUFACTURER
Haupt pharma Wolfratshausen GmbH
Pfaffenrieder Str. 5
82515 Wolfratshausen, Germany
Read the package insert carefully before use.
For any more information, please consult your doctor